Specialty Pharmacy

Sharing cancer data can save lives.

The contaminated fish was sourced from Sustainable Seafood Company and Santa Cruz Seafood.

Top news of the day from across the health care landscape.

Error reporting systems help to promote a culture of open communication in pharmacy.

Time to treatment initiation of cancer treatment increased between 2004 and 2013 from 21 days to 29 days, respectively.

Collaboration between Novartis and IBM Watson Health integrates real-world data and analytical techniques on breast cancer outcomes.

Sandoz is seeking approval of biosimilars adalimumab and infliximab for use in all indications of their respective reference products.

The findings could lead to speed the development of an HIV vaccine.

Top news of the day from across the health care landscape.

FDA approval of valbenazine (Ingrezza) for the iatrogenic movement disorder tardive dyskinesia shows impact of a well-executed development program.

The TZA test is faster, more cost-effective, and less labor-intensive than the current test for finding dormant HIV cells.

Initiating biologics before triple therapy increases costs and provides minimal incremental benefit.

An experimental drug reactivated an enzyme to elicit tumor suppression.

Switching from DMARDs to first-line biologics may not be the optimal treatment for RA.

GatherMS aims to fill the resource knowledge gap in the MS landscape.

Women accounted for most of the hospitalization and in-hospital deaths.

Top news of the day from across the health care landscape.

Health care has historically been physician-patient focused, but pharmacists and patients are changing this trend.

Outcomes-based contracting may soon play a role in the service level agreements between a specialty pharmacy provider and a manufacturer.

RA patients can consume up to 14 alcoholic beverages per week without increasing the risk of liver damage, but rates increase with increasing levels of alcohol consumption.

Gilead plans to file for approval of novel HIV drug in the United States and Europe this year.

Patient with MS was previously treated for 3 years with natalizumab, a known trigger of progressive multifocal leukoencephalopathy.

Continuous low-dose cisplatin through an implantable device could be a therapeutic option in for patients with ovarian cancer.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses trends in specialty drug cost management.

Top news of the day from across the health care landscape.

Metastatic urothelial carcinoma drug among key approvals from May 2017.

Statins also found to play key role in preventing cardiovascular events.

Rheumatoid arthritis drug among key FDA drug approvals from last month.